ANN ARBOR, MI / ACCESSWIRE / October 23, 2017 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, will hold a conference call on Wednesday, November 15, 2017 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2017. Financial results will be issued in a press release prior to the call.
ENDRA CEO Francois Michelon, CFO David Wells and CTO Michael Thornton will host the conference call, followed by a question and answer period.
To access the call, please use the following information:
Date: Wednesday, November 15, 2017
Time: 4:30 p.m. ET, 1:30 p.m. PT
Toll-free dial-in number: 1-877-397-0292
International dial-in number: 1-719-457-2644
Conference ID: 4056284
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at http://public.viavid.com/index.php?id=126860 and via the investor relations section of the Company's website at www.endrainc.com.
A replay of the conference call will be available after 7:30 p.m. Eastern time through November 29, 2017.
Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 4056284
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA's Photo-Acoustic Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models with high image quality and volume scanning speed. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound ("TAEUS") system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only on CT & MRI -- at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally. ENDRA's goal is to bring new capabilities to ultrasound -- thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.
Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com
Media & Investor Relations Contact:
MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us
SOURCE: ENDRA Life Sciences Inc.
ReleaseID: 478604
